Grantclosed🌐 United StatesRFA-CA-25-004

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

National Institutes of Health

Details?

Posted: Dec 16, 2024
Response deadline: Dec 9, 2025, 12:00 AM UTC
Type: Grant
Category: 93.394
Status: closed
Buyer: National Institutes of Health
Department: HHS-NIH11
Jurisdiction: United States
Reference #: RFA-CA-25-004

Doc Type: synopsis
Opp Status: archived

Similar past solicitations

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
United States · Dec 16, 2024
Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
United States · Dec 16, 2024
Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
United States · Dec 16, 2024
Dynamic and Adaptable Infrastructure for Drug Development and Outreach to Aid the Research Community in Advancing Medication Repurposing and Repositioning Efforts for Substance Use Disorders (SUDs) (U54 - Clinical Trials Not Allowed)
United States · Sep 24, 2025
Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)
United States · Nov 14, 2024
Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies (R33 Clinical Trial Optional)
United States · Nov 7, 2024

Finding similar opportunities…

This listing is a summary from United States's open procurement data. We ingest every field the feed publishes; the full solicitation documents are on the source portal.